Stoke Therapeutics Inc.
STOK | NASDAQ
$28.73
+$0.68 (+2.42%)
Sep 22, 2026, 11:50 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -264.50 | -6.68 | -2.21 | -3.55 | -10.25 | -39.70 |
PEG Ratio | 2.85 | 0.22 | 0.26 | -0.32 | -0.21 | 21.04 |
PS Ratio | 10.19 | 16.30 | 26.36 | 28.94 | n/a | n/a |
PB Ratio | 5.33 | 2.60 | 1.45 | 1.94 | 4.05 | 7.25 |
P/FCF Ratio | 41.85 | -6.84 | -2.80 | -10.02 | -12.94 | -47.93 |
P/OCF Ratio | 41.23 | -6.86 | -2.85 | -11.27 | -13.17 | -49.12 |
OCF/S Ratio | 24.72 | -237.59 | -923.31 | -256.88 | n/a | n/a |
Debt / Equity Ratio | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0 |
Quick Ratio | 5.28 | 5.81 | 6.99 | 7.77 | 13.37 | 25.73 |
Current Ratio | 5.28 | 5.81 | 6.99 | 7.77 | 13.37 | 25.73 |
Asset Turnover | 0.44 | 0.13 | 0.04 | 0.05 | n/a | n/a |
Interest Coverage | -2.29K | n/a | n/a | n/a | n/a | n/a |
Return on Equity | -1.95% | -38.85% | -65.62% | -54.68% | -39.40% | -18.26% |
Return on Assets | -1.65% | -32.77% | -45.85% | -39.47% | -35.92% | -17.54% |
Return on Invested Capital | -5.66% | -43.35% | -57.51% | -45.97% | -38.55% | -18.45% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 100% | 100% | 100% | 100% | n/a | n/a |
Net Profit Margin | -3.73% | -243.42% | -1.19K% | -814.73% | n/a | n/a |
Pretax Profit Margin | -3.73% | -243.42% | -1.19K% | -814.73% | n/a | n/a |
Operating Profit Margin | -11.16% | -277.31% | -1.31K% | -841.24% | n/a | n/a |
FCF Margin | 24.35% | -238.15% | -941.72% | -288.82% | n/a | n/a |
EBITDA Margin | -2.77% | -237.46% | -1.16K% | -802.27% | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove STOK